Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status

Kenneth Rockwood, Susan Howlett, John Fisk, Sultan Darvesh, Holly Tuokko, David B. Hogan, Christina Wolfson, Ian McDowell

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no cognitive impairment at either time. LLA use was associated with a lower odds of incident CIND in those
    Original languageEnglish
    Pages (from-to)201-207
    Number of pages6
    JournalNeuroepidemiology
    Volume29
    Issue number3-4
    DOIs
    Publication statusPublished - Feb 2008

    Keywords

    • Alzheimer's disease
    • Cognitive impairment, no dementia
    • Lipid-lowering agents
    • Mild cognitive impairment
    • Statins

    Fingerprint

    Dive into the research topics of 'Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status'. Together they form a unique fingerprint.

    Cite this